PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

This analysis describes the pharmacokinetic/pharmacodynamic (PK/PD) modeling framework that supported selection of the isatuximab (anti‐CD38 monoclonal antibody) dosing regimen alongside its early clinical development in patients with relapsed/refractory multiple myeloma (RRMM). The PK/PD mathematic...

Descripción completa

Detalles Bibliográficos
Autores principales: Koiwai, Kimiko, El‐Cheikh, Raouf, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean‐Baptiste, Veyrat‐Follet, Christine, Risse, Marie‐Laure, van de Velde, Helgi, Semiond, Dorothée, Nguyen, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376141/
https://www.ncbi.nlm.nih.gov/pubmed/34185964
http://dx.doi.org/10.1002/psp4.12666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376141/
https://www.ncbi.nlm.nih.gov/pubmed/34185964
http://dx.doi.org/10.1002/psp4.12666

Ejemplares similares